Marta Pajares Cabetas

Academic background

• Biochemistry High Degree at the Universidad Autónoma de Madrid in June 2013.
• Master in Molecular Biomedicine at the Universidad Autónoma de Madrid, June 2014.
• PhD student belonging to the Doctorate Program in Biochemistry, Molecular Biology, Biomedicine and Biotechnology (Molecular Biosciences) in Prof. Cuadrado laboratory at the Universidad Autónoma de Madrid, currently.

Publications

• Cuadrado A, Manda G, Ahmed H, Alcaraz MJ, Barbas C, Daiber A, Ghezzi P, León R, G. López M, Oliva B, Pajares M, Rojo AI, Robledinos-Antón N, Valverde AM, Guney E, Schmidt H.H.W. Transcription factor NRF2 as a therapeutic target for degenerative diseases: a systems medicine approach. Pharmacol. Rev. In press.
• Rojo AI, Pajares M, Rada P, Nuñez A, Nevado-Holgado AJ, Killik R, Van Leuven F, Ribe E, Lovestone S, Yamamoto M, Cuadrado A.NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. Redox Biol. 2017 Oct;13:444-451.
• Pajares M, Cuadrado A, Rojo AI. Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biol. 2017 Apr;11:543-553.
• Pajares M, Jiménez-Moreno N, García-Yagüe AJ, Escoll M, Ceballos ML, Leuven FL, Rábano A, Yamamoto M, Rojo AI and Cuadrado A. Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy. 2016 Oct 2;12(10):1902-1916.
• Pajares M, Jiménez-Moreno N, Dias I, Debelec B, Vucetic M, Fladmark K, Basaga H, Ribaric S; Milisav I y Cuadrado A. Redox control of protein degradation. Redox Biol. 2015 Dec;6:409-20. 
• Zahonero C, Aguilera P, Ramírez-Castillejo C, Pajares M, Bolos MV, Cantero D, Perez-Nuñez A, Hernández-Laín A, Sánchez-Gómez P, Sepúlveda JM. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol Cancer Ther. 2015.